Impact of the introduction of rituximab in first-line follicular lymphoma: A retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up

Hematological Oncology

Volumn 33, Issue 1, 2015, Pages 1-8

  Nicolas Virelizier, Emmanuelle ^a   Ségura Ferlay, Céline ^a   Ghesquières, Herve ^a   Chassagne Clément, Catherine ^a   Gargi, Thérèse ^a   Biron, Pierre ^a   Belhabri, Amine ^a   Rey, Philippe ^a   Faurie, Pierre ^a   Chabaud, Sylvie ^a   Sebban, Catherine ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Daily practice; FLIPI; Follicular lymphoma; Rituximab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME; DISEASE FREE SURVIVAL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925641941     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2130     Document Type: Article

References (27)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780-2795.
2. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
3. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
4. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
6. Herold M, Haas A, Srock S, et al. East German study group hematology and oncology study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007; 25: 1986-1992.
7. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831.
8. Ghesquieres H, Ferlay C, Sebban C, et al. Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. Hematol Oncol 2008; 26: 139-147.
9. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 1982; 49: 2112-2135.
10. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-1117.
11. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes. Blood 2006; 108: 2540-2544.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
16. Cox D. Regression model and lifer tables (with discussion). J R Stats Soc 1972; 34: 187-220.
17. Krause SW, Gerken M, Andreesen R, Hofstädter F, Klinkhammer-Schalke M. Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Ann Hematol 2012; 91: 561-570.
18. Sacchi S, Pozzi S, Marcheselli L, et al. Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109: 2077-2082.
19. Overman MJ, Feng L, Pro B, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 2008; 19: 553-559.
20. Ardeshna KM, Smith P, Norton A, et al. British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
21. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
22. Colombat P, Salles G, Brousse N, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol 2012; 23: 2380-2385.
23. Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012; 30: 3848-3853.
24. Numata A, Tomita N, Fujimaki K, et al. Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP. J Clin Exp hematop 2012; 52: 77-79.
25. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
26. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555-4562.
27. Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010; 149: 455-457.